In vitro comparison of the vitamin D endocrine system in 1,25(OH)2D3-responsive and -resistant melanoma cells

Cancer Biology and Therapy

Volumn 6, Issue 1, 2007, Pages 48-55

  Reichrath, Jörg ^a   Rech, Martin ^a   Moeini, Maryam ^a   Meese, Eckart ^a   Tilgen, Wolfgang ^a   Seifert, Markus ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Cancer; Malignant melanoma; Real time polymerase chain reaction; Vitamin D

Indexed keywords

CALCIFEDIOL; CALCITRIOL; MESSENGER RNA; OXYGENASE; RNA; SEOCALCITOL; VITAMIN D RECEPTOR;

ARTICLE; CANCER GROWTH; CELL LINE; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOCRINE SYSTEM; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; PALLIATIVE THERAPY; PATHOGENESIS; PROTEIN EXPRESSION; VITAMIN METABOLISM;

EID: 33847096445     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.1.3493     Document Type: Article

References (33)

1. 3 and its analogs on growth control and tumorigenesis. Front Biosci 2001; 6:820-48.
2. Seifert M, Rech M, Meineke V, Tilgen W, Reichrath J. Differential biological effects of 1,25-dihydroxyVitamin D3 on melanoma cell lines in vitro. J Steroid Biochem Mol Biol 2004; 90:375-9.
3. Osborne JE, Hutchinson PE. Vitamin D and systemic cancer: Is this relevant to malignant melanoma? Br J Dermatol 2002; 147:197-213.
4. Danielsson C, Fehsel K, Polly P, Carlberg C. Differential apoptotic response of human melanoma cells to 1 alpha,25-dihydroxyvitamin D3 and its analogues. Cell Death Differ 1998; 5:946-52.
5. 3 and malignant melanoma: The presence of receptors and inhibition of cell growth in culture. Endocrinology 1981; 108:1083-6.
6. 3 in intestinal tract, stomach, kidney, skin, pituitary and parathyroid. Science 1979; 209:1189-90.
7. Baker AR, McDonnell DP, Hughes M. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci USA 1988; 85:3294-8.
8. 3 signalling. Nature 1992; 355:446-9.
9. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988; 240:889-95.
10. 3 (calcitriol) open a new era in cancer therapy? Onkologie 2001; 24:128-33.
11. Jones G, Ramshaw H, Zhang A, Cook R, Byford V, White J, Petkovich M. Expression and activity of vitamin D-metabolizing cytochrome P450s (CYP1a and CYP24) in human a nonsmall cell lung carcinomas. Endocrinology 1999; 140:3303-10.
12. Tangpricha V, Flanagan JN, Whitlatch LW, Tseng CC, Chen TC, Holt PR, Lipkin MS, Holick MF. 25-hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon tissue. Lancet 2001; 357:1673-4.
13. Henry HL. Vitamin D hydroxylase. J Cell Biochem 2001; 49:4-9.
14. Nebert DW, Gonzalez FJ. P450 genes: Structure, evolution, and regulation. Ann Rev Biochem 1987; 56:945-93.
15. 3 (calcitriol). J Dermatol Sci 1998; 18:118-27.
16. Bell NH. Renal and nonrenal 25-hydroxyvitamin D-1alpha-hydroxylases and their clinical significance. J Bone Miner Res 1998; 13:350-3.
17. 3 by a human small cell lung cancer cell line. J Clin Endocrinol Metab 1994; 79:554-60.
18. Adams JS. In: Feldman D, Glorieux F, Pike W, eds. Vitamin D, chapt 55. San Diego: Academic Press, 1997:55:903-23.
19. Goltzman D, Henderson JE. In: Bilezekian J, Raisz L, Rodan G, eds. Principles of Bone Biology, chapt 58. San Diego, CA: Academic Press, 1996:58:809-26.
20. Gupta PB, Kuperwasser C, Brunet JP, Ramaswamy S, Kuo WL, Gray JW, Naber SP, Weinberg RA. The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet 2005; 37:1047-54.
21. Palmer HG, Larriba MJ, Garcia JM, Ordonez-Moran P, Pena C, Peiro S, Puig I, Rodriguez R, de la Fuente R, Bernad A, Pollan M, Bonilla F, Gamallo C, de Herreros AG, Munoz A. The transcription factor SNAIL represses vitamin D receptor expression and responsiveness in human colon cancer. Nat Med 2004; 10:917-9.
22. des Grottes JM, Dumon JC, Body JJ. Hypercalcaemia of melanoma: Incidence, pathogenesis and therapy with bisphosphonates. Melanoma Res 2001; 11:477-82.
23. Attia P, Phan GQ, Duray PH, Rosenberg SA. Parathyroid hormone-related protein and hypercalcemia in patients with metastatic melanoma: Case report and review. Am J Clin Oncol 2003; 26:42-5.
24. Hewison M, Zehnder D, Bland R, Stewart PM. 1alpha-Hydroxylase and the action of vitamin D. J Mol Endocrinol 2000; 25:141-8.
25. Tanaka Y, DeLuca HF. Stimulation of 24,25-dihydroxyvitamin D3 production by 1,25-dihydroxyvitamin D3. Science 1974; 183:1198-200.
26. Brenza HL, Kimmel-Jehan C, Jehan F, Shinki T, Wakino S, Anazawa H, Suda T, DeLuca HF. Parathyroid hormone activation of the 25-hydroxyvitamin D3-1alpha-hydroxylase gene promoter. Proc Natl Acad Sci USA 1998; 95:1387-91.
27. Maas RM, Reus K, Diesel B, Steudel WI, Feiden W, Fischer U, Meese E. Amplification and expression of splice variants of the gene encoding the P450 cytochrome 25-hydroxyvitamin D(3) 1,alpha-hydroxylase (CYP 27B1) in human malignant glioma. Clin Cancer Res 2001; 7:868-75.
28. Diesel B, Fischer U, Meese E. Gene amplification and splice variants of 25-hydroxyvitamin D3 1,alpha-hydroxylase (CYP27B1) in glioblastoma multiforme-a possible role in tumor progression? Recent Results Cancer Res 2003; 164:151-5.
29. Diesel B, Seifert M, Radermacher J, Fischer U, Tilgen W, Reichrath J, Meese E. Towards a complete picture of splice variants of the gene for 25-hydroxyvitamin D31alpha-hydroxylase in brain and skin cancer. J Steroid Biochem Mol Biol 2004; 90:527-32.
30. Ding S, Lake BG, Friedberg T, Wolf CR. Expression and alternative splicing of the cytochrome P-450 CYP2A7. Biochem J 1995; 306:161-6.
31. Stimpfl M, Tong D, Fasching B, Schuster E, Obermair A, Leodolter S, Zeilinger R. Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer. Clin Cancer Res 2002; 8:2253-9.
32. Adams M, Jones JL, Walker RA, Pringle JH, Bell SC. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease. Cancer Res 2002; 62:3289-97.
33. Wang Z, Lo S, Yang H, Gere S, Hu Y, Buetow H, Lee MP. Computational analysis and experimental validation of tumor-associated alternative RNA splicing in human cancer. Cancer Res 2003; 63:655-7.